Abstract
Methods Cross-sectional, multicenter, national survey. The following data were collected: age, sex, type of psoriasis, swollen and tender joint counts (SJ 44/TJ 46), ESR (mm/1hora), CRP (mg/dL), DAS28, Psoriasis Global Assessment (PGA), Physician Global Assessment (PhyGA), Patient Global Assessment (PatGA), pharmacological therapy taken (AINEs, glucocorticoids, DAMARDs, and anti-TNFalfa therapy), Visual Analogue Scale (VAS) of pain, Disease impact as measured by VAS in the personal, occupational and social spheres, Health Assessment Questionnaire (HAQ) and Dermatology Life Quality Index (DLQI).
Highlights
Twenty four percent of patients had a moderate-severe extent of PsA as measured by Psoriasis Global Assessment (PGA)
Of 173 patients from whom DAS28 was available, 38% were en remission (DAS282.63.2). 98.6% of patients were taken drugs for treatment of psoriatic arthritis: 21% oral glucocorticoids (
Disease impact measured by Visual Analogue Scale (VAS) in the personal sphere was higher in females than in males (31.2 (2537.4) vs 22.1 (16.7-27.5); p
Summary
National survey of patients with psoriatic arthritis in Spain: disease activity, pharmacological therapy and impact on quality of life From 5th European Workshop on Immune-Mediated Inflammatory Diseases Sitges-Barcelona, Spain. Objective To evaluate disease activity, management with pharmacological therapy and the impact on functional capacity and quality of life of psoriatic arthritis in Spain.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
